CD22
Other names: CD22 antigen
CD22 is a marker on B cells used as a target in some leukemias and B-cell lymphomas.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Plain explanation
CD22 is a surface protein of B cells. When B cells become malignant, this protein can remain present so it can be used as a therapeutic target.
Clinical meaning
CD22 positivity is used in consideration of conjugated antibody therapy and some cellular therapy studies in acute lymphoblastic leukemia and B cell lymphoma.
Testing methods
- Flow cytometry
A test that rapidly measures cell-surface markers across many cells.
- Immunohistochemistry (IHC)
A test that uses antibodies to mark specific proteins in tumour tissue.
A negative result does not always mean the marker is absent
Test sensitivity differs by sample type and method. Results need to be read together with the pathology report and clinical condition.
What needs verification
- Percentage of cells expressing CD22 in the cell flow assay.
- Changes in markers after previous therapy, including possible loss of markers.
- Compliance with study protocol criteria when considering cellular therapy.
Related drugs
- Inotuzumab ozogamicin
Anti-CD22 antibody-drug conjugate
A link here means the marker is often part of considering a drug category, not a recommendation to use it.
Treatment categories
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Clinical trials
Studies mentioning this marker
Filtered from public study descriptions. Access status and site readiness remain unverified.
NO DATA
No studies in the latest registry data mention this marker in their description.
Check options based on your result
Share the CD22 result you have so we can explain which categories to discuss with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Leukemia
Cancer type
Reason: Related through a biomarker
- Lymphoma
Cancer type
Reason: Related through a biomarker
- CD22 positive
Molecular alteration
Reason: Related through a biomarker
- CAR-T (chimeric antigen receptor T-cell therapy)
Treatment category
Reason: Related through a biomarker
- Targeted therapy
Treatment category
Reason: Related through a biomarker
- Inotuzumab ozogamicin
Drug
Reason: Targets this marker
To check
- Flow cytometry
Diagnostic test
Reason: Diperiksa melalui
- Immunohistochemistry (IHC)
Diagnostic test
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.